← Eichor
Study identifier: NCT06416748 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Minimally Invasive Simple Hysterectomy in Low Risk Cervical Cancer

Condition: Cervical Cancer · Cervix Cancer  ·  Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

PhaseNA
Planned participants974
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The rationale of the present study is to assess the safety of the minimally invasive surgery approach in patients meeting the SHAPE trial inclusion criteria.The SHAPE trial was designed to answer the clinical question of whether simple hysterectomy could be performed instead of radical hysterectomy in low-risk early stage cervical cancer but not the surgical approach. The favorable oncological outcome observed in SHAPE despite 75% of patients were treated with minimally invasive approach suggests that this approach may be safe. However, the trial was not designed to analyze oncological outcomes from surgical approach.

This description comes directly from the study's public registry record.

Talk to the study team

Nicolò Bizzarri, MD  ·  0630155629  ·  nicolo.bizzarri@yahoo.com

Matteo Pavone, MD  ·  0630155629  ·  matteopavone.21@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fondazione Policlinico Universitario A. Gemelli IRCCSRoma, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06416748